# Felodipine Controlled Release Tablets and Felodipine Sustained Release Tablets in Healthy Subjects Under Fasting State Comparative Pharmacokinetic Study

> **NCT05614037** · PHASE1 · UNKNOWN · sponsor: **Overseas Pharmaceuticals, Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Felodipine sustained release tablets (trade name: plendil®)
- **DRUG:** Felodipine Controlled Release Tablets

## Key facts

- **NCT ID:** NCT05614037
- **Lead sponsor:** Overseas Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-28
- **Primary completion:** 2022-11-20
- **Final completion:** 2023-03-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05614037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05614037, "Felodipine Controlled Release Tablets and Felodipine Sustained Release Tablets in Healthy Subjects Under Fasting State Comparative Pharmacokinetic Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05614037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*